Search International and National Patent Collections

1. (WO2017200969) COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS

Pub. No.:    WO/2017/200969    International Application No.:    PCT/US2017/032790
Publication Date: Fri Nov 24 00:59:59 CET 2017 International Filing Date: Wed May 17 01:59:59 CEST 2017
IPC: A61K 39/395
A61K 45/06
A61K 31/542
A61P 35/00
Applicants: ELI LILLY AND COMPANY
Inventors: BENDER, Mark Harrath
GAO, Hong
PATEL, Bharvin Kumar
Title: COMBINATION THERAPY WITH NOTCH AND PD-1 OR PD-L1 INHIBITORS
Abstract:
The present invention provides medicaments for use in treating and methods of treating T- cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, Sung cancer, non small-cell lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral squamous cell carcinoma, skin cancer, medul!ob!astoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, desmoid tumor, soft tissue sarcoma, or adenoid cystic carcinoma in a patient comprising combination therapy with 4,4,4-trifluoro-N-[(1S)-2~[[(7S)-5-(2-hydroxyemyl)-6-oxo-7H-pyrido[23-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo- ethyljbutanamide, or a pharmaceutically acceptable salt or hydrate thereof, and a PD-1 or a PD-L1 inhibitor selected from pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab.